Delcath Systems

DCTH

Market cap $374M

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced that its proprietary CHEMOSAT® Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (M-PHP) has been included as a recommended liver-directed regional therapy option in the newly published Uveal Melanoma: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up (April 2026). M-PHP is also re.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place April 11–15, 2026, in Toronto, Canada. At the event, Delcath's Hepatic Delivery System for use in percutaneous hepatic perfusion will be featured in three presentations. On April 13, 2026, at 2:40 PM ET, Dr. Eric We.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), (“Delcath” or the “Company”) an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of the full results from the investigator-initiated CHOPIN randomized Phase 2 clinical trial, led by Principal Investigator Professor Ellen Kapiteijn, MD, from Leiden University Medical Center's Department of Medical Oncology. The publication, titled “Percutaneous.

Delcath Systems, Inc.'s revenue remains under pressure due to weak patient starts in the third quarter of 2025. The fundamentals of the company remain intact, though, and 2026 should be another year of strong growth. Delcath's profitability will be under pressure due to investments in clinical trials and sales and marketing.

Delcath Systems, Inc. (DCTH) Q4 2025 Earnings Call Transcript

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported financial results and business highlights for the fourth quarter and full year-ended December 31, 2025. Fourth Quarter and Full Year 2025 Financial Results Total fourth quarter and full year revenue of $20.7 million and $85.2 million, respectively HEPZATO KIT™ fourth quarte.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on February 26, 2026, at 8:30 AM Eastern Time to discuss results for its fourth quarter and full year ended December 31, 2025. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the beginning of the call. Event Date: Th.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference at the Cliff Lodge in Snowbird, Utah. About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT Delcath Systems, Inc. is an interventional oncology company focused on the treatmen.

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as material inducements to four individuals whose employment commenced in either November 2025 or December 2025. The grants, in the form of Restricted Stock Units (RSUs), totaled.

Delcath Systems is upgraded from Hold to Buy as sales stabilize and insider confidence grows. DCTH expects to hit the upper end of 2025 guidance at $85M, signaling operational stabilization after earlier guidance cuts. CHOPIN trial results expand HEPZATO's potential beyond liver therapies, supporting a broader market opportunity.